About Novartis
Novartis is a Healthcare company based in Stevenage (United Kingdom) founded in 2016, and was acquired by Novartis in December 2021. Gene therapies for eye diseases, focusing on AMD, are developed. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Novartis has raised $255.04 million across 5 funding rounds from investors including Novartis, T. Rowe Price and Sanofi. Novartis has completed 1 acquisition, including Orbit Biomedical. Novartis offers products and services including Zolgensma and Cosentyx. Its focus areas include Pharmaceuticals and Biotechnology. Its legal entity is Novartis AG.
Company details
Novartis is established as a global leader in innovative medicines, focusing on reimagining healthcare to improve and extend lives. The company operates in key therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. Solutions are developed to address significant disease burdens, reaching 296 million people worldwide. Research and development efforts are centered on breakthrough science, with a robust pipeline of transformative treatments. Novartis is committed to societal impact through access programs, environmental sustainability, and ethical standards.
Products & Services of Novartis
Novartis offers a comprehensive portfolio of products and services, including Zolgensma and Cosentyx.
Gene therapy for spinal muscular atrophy is provided.
Treatment for autoimmune diseases is offered by Novartis.
Apps and channels of Novartis
its YouTube channel Novartis has 49.9K subscribers and 30 videos.
Videos from Novartis
The most watched videos on Novartis's YouTube channel, Novartis (49.9K subscribers). Click a video to play it here.
More on Novartis.
Funding Insights of Novartis
Novartis has successfully raised a total of $255.04M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $255.04M
- Total Rounds 5
- Last Round Series C — $40M
- First Round $6.24M
(Jun 2016)
- Investors Count 10
All 5 funding rounds of Novartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $40M | Series C | – | Sanofi | – |
| Mar 2021 | $148M | Series C | – | Forbion | |
| Sep 2019 | $60.8M | Series B | – | Syncona | |
| Mar 2019 | Series A | – | Cambridge Innovation Capital | – | |
| Jun 2016 | $6.24M | Series A | – | Syncona, Cambridge Enterprise | – |
11 investors in total: 11 institutional.
Investors in Novartis
Novartis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, T. Rowe Price and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in life sciences and deep tech. | 2013 | cic.vc | Cambridge, United Kingdom | |
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
| cicplc.co.uk | ||||
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Diversified investment management services are offered across multiple asset classes. | 2005 | tetragoninv.com | New York, United States | |
Research, development, production, and sale of pharmaceuticals are provided. | 1994 | fosunpharma.com | Shanghai, China | |
Provider of intellectual property management and technology consulting services | 2006 | enterprise.cam.ac.uk | Cambridge, United Kingdom |
Investor details for Novartis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novartis
48 people are tracked at Novartis (15 in leadership, 20 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Khurem Farooq | CEO & Board Member | Leadership |
Jane Hughes | Chief Scientific Officer | Leadership |
Nadia Waheed | Chief Medical Officer | Leadership |
Charmaine O'Neill | Associate Director Clinical Operations | Leadership |
Scott Ellis | Head Of Research And Development | Leadership |
Matthew Enos | Associate Clinical Development Director | Pipeline Medical Team | Leadership |
Rachel Sartaj | Associate Clinical Development Director | Leadership |
Kamila Pytel | Associate Director CMC Analytical Development | Leadership |
Jenny Dines | Director Of People (rest Of World) | Leadership |
Kate Archer | Director, Corporate Affairs | Leadership |
Ingrid Boyes | Chief People Officer | Leadership |
Jessica Stitt | Chief Financial Officer | Leadership |
Stephanie Saddic | Senior Director | Leadership |
Lisa Giles | Head Of Pipeline & Portfolio Strategy | Leadership |
Edward Lang Jr | Chief Business Officer | Leadership |
Keith Peters | Scientific Advisory Board Member | Board & advisors |
Alberto Auricchio | Scientific Advisory Board Member | Board & advisors |
Pete Coffey | Scientific Advisory Board Member | Board & advisors |
Robert Maclaren | Scientific Advisory Board Member | Board & advisors |
Matthew Pickering | Scientific Advisory Board Member | Board & advisors |
28 more people are available in the full profile.
Complete people profiles for Novartis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novartis
Novartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orbit Biomedical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Medical device for ophthalmic surgery is developed. | orbitbiomedical.com | Ambler, United States | 2018 | Apr 2019 | •••• |
Complete acquisition details for Novartis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novartis
5 dated milestones of Novartis across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Novartis is founded.
- Funding First funding round of $6.2M.
- Acquisition Acquires Orbit Biomedical.
- Funding Latest funding round, Series C, of $40.0M.
- Exit Acquired by Novartis.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Novartis (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novartis
Complete news archive for Novartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novartis
Novartis was founded in 2016.
Novartis is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Novartis is a funded company, having raised a total of $255.04M across 5 funding rounds to date. The company's 1st funding round was a Series A of $6.24M, raised on Jun 2016.
Novartis is established as a global leader in innovative medicines, focusing on reimagining healthcare to improve and extend lives. The company operates in key therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. Solutions are developed to address significant disease burdens, reaching 296 million people worldwide. Research and development efforts are centered on breakthrough science, with a robust pipeline of transformative treatments. Novartis is committed to societal impact through access programs, environmental sustainability, and ethical standards.
Novartis offers Zolgensma and Cosentyx.
Novartis has made 1 acquisition, including Orbit Biomedical.
Novartis has 11 investors. Key investors include Novartis, T. Rowe Price, Sanofi, Syncona, and Fosun Pharmaceutical.
Novartis operates through Novartis Ag.
Yes. Novartis was acquired by Novartis in December 2021.